VentiRx Pharma Raises $25 Million
VentiRx Pharmaceuticals Inc., a San Diego-based drug company initially focused on small molecule Toll-like receptor (TLR)-based therapeutics, has raised $25 million in additional Series A funding. The company previously announced $26.6 million in Series A funding nearly two years ago, which came on top of a $2.3 million seed round. MedImmune Ventures led the new tranche, and was joined by return backers Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates.
12 January 2010•3 mins read
